Enterprise Value
245.6M
Cash
625M
Avg Qtr Burn
-163.3M
Short % of Float
48.06%
Insider Ownership
0.44%
Institutional Own.
61.54%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nuvaxovid (NVX-CoV2373) Details COVID-19 | Approved Update | |
Phase 3 Data readout | ||
Novavax COVID-NanoFlu combination (NVX-CoV2373) + Matrix-M™ Details Influenza, COVID-19 | Phase 3 Data readout | |
RSV Vaccine Details Respiratory syncytial virus | Phase 3 Update | |
RSV Vaccine Details Respiratory syncytial virus | Phase 2 Update | |
NanoFlu vaccine Details Influenza | Phase 2 Initiation | |
RSV Vaccine Details Respiratory syncytial virus | Phase 1 Update |